The role of receptors in multistage carcinogenesis

H C Pitot1

  • 1McArdle Laboratory for Cancer Research, Departments of Oncology and Pathology, University of Wisconsin, Madison 53706, USA.

Mutation Research
|December 1, 1995
PubMed

Insights

Cancer develops through genetic expression changes. Preventing the reversible promotion stage by removing environmental agents offers the best cancer prevention opportunity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neoplasia is characterized by inherited alterations in genetic expression.
  • Gene expression regulation can be modified by mutations and environmental factors.
  • Carcinogenesis involves both reversible promotion and irreversible progression stages.

Purpose of the Study:

  • To explore the role of environmental mediators and receptor interactions in carcinogenesis.
  • To identify the promotion stage as a critical window for cancer prevention.
  • To propose a rational risk estimation for promoting agents based on their interaction with cellular receptors.

Main Methods:

  • The study focuses on the mechanisms of gene expression alteration during carcinogenesis.
  • It examines the reversible promotion stage mediated by ligand-receptor interactions.
  • Apoptosis as a consequence of promoter withdrawal is considered.

Main Results:

  • Chronic ligand-receptor interaction during promotion increases the likelihood of progression to malignancy.
  • Reversible alterations in gene expression occur during the promotion stage.
  • Withdrawal of promoting agents can reverse effects and induce apoptosis in promoted cells.

Conclusions:

  • Intervention during the reversible promotion stage is key for cancer prevention.
  • Targeting ligand-receptor interactions offers a strategy to inhibit carcinogenesis.
  • Understanding these mechanisms allows for better risk assessment of environmental carcinogens.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...